MedTrace Logo

Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105

NCT05289726 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2022-03-21

No results posted yet for this study

Summary

this is an preventive study to evaluate the preventive effect of traditional chinese medicine TDX105 on Regorafenib induced Dermatologic Toxicities

Conditions

  • Hand and Foot Skin Reaction
  • Colorectal Cancer Stage IV

Interventions

DRUG

Traditional chinese medicine TDX105

Experimental group Traditional chinese medicine TDX105

DRUG

Placebo

he control group received placebo granules mixed with dextrin and food coloring

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-18
Primary Completion
2022-07-18
Completion
2023-04-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05289726 on ClinicalTrials.gov